Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA To Update Quality Metrics Guidance

Executive Summary

It's the only addition to the agency's 2016 agenda.


Related Content

False Claims, Enforcement Changes Possible Under Trump Administration
Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Biosimilar Labeling: FDA Says Leave Comparability Data Out
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
FDA Urged to Phase In Quality Metrics Over Two-Year Period
Industry: FDA Underestimated Burden of Metrics Reporting
FDA GMP Quality Metrics Will Be Industry’s ‘SAT Score’
Drug GMP “Surveillance” Will Link Compliance Information To Inspections


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts